Moderna gets further $472 million US award for coronavirus vaccine development

Moderna gets further $472 million US award for coronavirus vaccine development
The US government awarded another $472m to US biotech Moderna to support the phase 3 clinical trials on July 26, 2020. (File/AFP)
Short Url
Updated 26 July 2020

Moderna gets further $472 million US award for coronavirus vaccine development

Moderna gets further $472 million US award for coronavirus vaccine development
  • The funding will support late-stage clinical development of the vaccine and the phase 3 trials.

WASHINGTON D.C: Moderna Inc. said on Sunday it has received an additional $472 million from the US government’s Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.
The US-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna’s vaccine candidate.
In April, Moderna had received $483 million from the US federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the US National Institutes of Health.
“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” Chief Executive Officer Stéphane Bancel said in a press release.
BARDA’s total funding for the experimental vaccine of Moderna, the first in the United States to begin human trials of a coronavirus vaccine, is now about $955 million.
The vaccine uses synthetic messenger RNA (mRNA) to inoculate against the coronavirus. Such treatments help the body immunize against a virus and can potentially be developed and manufactured more quickly than traditional vaccines.
A Phase 3 study, conducted in collaboration with the National Institute of Allergy and Infectious Diseases, will begin on July 27 and involve about 30,000 participants, according to the company.
Moderna said it remains on track to be able to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021.
The announcement about further funding came two days after the drug developer said its formula used in developing the vaccine was not covered under patents owned by Arbutus Biopharma.
Pfizer Inc, Novavax Inc, Britian’s AstraZeneca Plc are other few drug makers that received funding from BARDA for coronavirus vaccine development.


More risks to pregnant women, their newborns from COVID-19 than known before — study

More risks to pregnant women, their newborns from COVID-19 than known before — study
Updated 19 min 16 sec ago

More risks to pregnant women, their newborns from COVID-19 than known before — study

More risks to pregnant women, their newborns from COVID-19 than known before — study
  • An infection of the new coronavirus in such newborns is associated with a three-fold risk of severe medical complications
  • The study was conducted in more than 2,100 pregnant women across 18 countries

Pregnant women infected with COVID-19 and their newborn children face higher risks of complications than was previously known, a study by British scientists showed on Friday.
An infection of the new coronavirus in such newborns is associated with a three-fold risk of severe medical complications, according to a study conducted by scientists at the University of Oxford. 
While pregnant women are at higher risk of complications such as premature birth, high blood pressure with organ failure risk, need for intensive care and possible death.
“Women with COVID-19 during pregnancy were over 50% more likely to experience pregnancy complications compared to pregnant women unaffected by COVID-19,” said Aris Papageorghiou, co-lead of the trial and a professor of fetal medicine at Oxford University.
The study was conducted in more than 2,100 pregnant women across 18 countries, where each woman affected by COVID-19 was compared to two non-infected women giving birth at the same time in the same hospital.
Findings from the study, published in the medical journal JAMA Pediatrics, also showed a delivery by caesarean section may be associated with an increased risk of virus infection in newborns.
However, breastfeeding does not seem to heighten risks of babies contracting COVID-19 from their mothers, scientists said.


UK study finds significant drop in COVID-19 infections after one jab

UK study finds significant drop in COVID-19 infections after one jab
Updated 23 April 2021

UK study finds significant drop in COVID-19 infections after one jab

UK study finds significant drop in COVID-19 infections after one jab
  • Infections in adults of all ages fell by 65% after a first dose of AstraZeneca or Pfizer vaccine
  • More than 33 million people in Britain have received a first dose of a COVID-19 vaccine

LONDON: COVID-19 infections in adults of all ages fell by 65% after a first dose of AstraZeneca or Pfizer vaccine in UK research, which scientists said showed the real-world impact of the nation’s immunization campaign against the pandemic.
Crucially, the research was conducted at a time when a new and more infectious variant of the coronavirus, called B1.1.7, was dominant in Britain, but still found vaccination was just as effective in elderly people and those with underlying health conditions as it was in the young and healthy.
“These real-world findings are extremely promising,” health minister James Bethell said in a statement as the data were published. He said they showed Britain’s COVID-19 vaccination program — one of the world’s fastest — was having a “significant impact.”
The data come from two studies that are part of the COVID-19 Infection Survey — a collaboration between Oxford University, the government’s health department, and the Office of National Statistics. Both studies were published online as preprints on Friday and have not yet been peer-reviewed.
The researchers analyzed more than 1.6 million test results from nose and throat swabs taken from 373,402 study participants between Dec. 1, 2020 and April 3, 2021.
They found that 21 days after a single dose of either the AstraZeneca or Pfizer-BioNTech vaccine — with no second dose — rates of all new COVID-19 infections had dropped by 65%.
This included a drop in symptomatic infections by 74% and a drop in infections with no reported symptoms by 57%.
Reductions in overall infections and in symptomatic infections, were even greater after a second dose — 70% and 90% respectively — the study found, and were similar to effects in people who had previously had a COVID-19 infection.
The second study looked at levels of antibodies to the SARS-CoV-2 virus to see how they changed after one dose of either vaccine, and after two Pfizer doses.
Results showed that antibody responses to a single dose of either vaccine were slightly lower in older people, but high across all ages after two Pfizer doses.
More than 33 million people in Britain have received a first dose of a COVID-19 vaccine, with more than 10 million having had two doses, official data showed on Wednesday.


Manhattan subway bomber sentenced to life in prison

Akayed Ullah, a Bangladeshi immigrant, was sentenced to life in a US prison on April 22 2021 for attempting to blow up himself and others in Times Square subway station, New York. (File/AFP)
Updated 23 April 2021

Manhattan subway bomber sentenced to life in prison

Akayed Ullah, a Bangladeshi immigrant, was sentenced to life in a US prison on April 22 2021 for attempting to blow up himself and others in Times Square subway station, New York. (File/AFP)
  • Akayed Ullah, 31, claimed he wanted to kill only himself and was not acting on behalf of Daesh
  • Ullah will serve a minimum of 35 years behind bars

NEW YORK: A Bangladeshi man convicted of setting off a pipe bomb during rush hour in New York City’s busiest subway station, Times Square, was sentenced on Thursday to life plus 30 years in prison.
Akayed Ullah, 31, of Brooklyn, had claimed he wanted to kill only himself and was not acting on behalf of Daesh when he detonated his homemade bomb on Dec. 11, 2017.
No one died and four people were injured in the explosion, which led to the temporary closure of the station and the adjacent Port Authority Bus Terminal during the morning rush. Ullah was burned in what prosecutors called a “lone wolf” attack.
US Circuit Judge Richard Sullivan, who imposed the sentence, told Ullah he had committed a “truly barbaric and heinous crime” without regard for the humanity of those in his way.
“They were just people on the way to work, or school,” Sullivan said. “People who maybe had finished the night shift. ... To you, these people were expendable.”
Ullah, who is married and has a 3-year-old son, had faced a mandatory minimum 35-year term.
He told Sullivan he did not condone violence, and apologized to New York City, law enforcement and the United States.
“What I did on December 11, it was wrong,” Ullah said. “I can tell you from the bottom of my heart, I’m deeply sorry.”
Prosecutors said Ullah was angry with then-President Donald Trump and with US foreign policy in the Middle East, and that Daesh propaganda inspired him to kill, maim and terrorize as many commuters as possible.
“Akayed Ullah’s message of hatred clearly backfired,” US Attorney Audrey Strauss said in a statement.
At the time of the attack, Ullah had a green card, allowing him to live in the United States.
He lived with his mother, sister and two brothers in Brooklyn, while his wife and then-infant son lived in Bangladesh.
Ullah’s lawyer Amy Gallicchio, a federal public defender, called him a “deeply troubled soul” who had been attracted on the Internet to the “distorted and radical messages” of extremism.
“He is not an evil man,” Gallicchio said, a sentiment the judge also expressed. “He is not a monster.”
But federal prosecutor Rebekah Donaleski questioned why Ullah chose Times Square to set off the bomb if suicide was his goal.
The bomb materials had come from a nearby construction site where Ullah worked as an electrician.
“It is important to send a message that when you attack New York City, there will be no leniency,” Donaleski said.
Ullah was convicted in November 2018. Sullivan presided over Ullah’s case when he was a federal district judge.


Thousands gather to wish Chad’s slain president “a deserved rest“

Thousands gather to wish Chad’s slain president “a deserved rest“
Updated 23 April 2021

Thousands gather to wish Chad’s slain president “a deserved rest“

Thousands gather to wish Chad’s slain president “a deserved rest“
  • French President Emmanuel Macron, Guinean President Alpha Conde and several other African leaders were expected to attend the funeral
  • Deby ruled Chad for more than 30 years and was one of Africa’s wiliest political survivors

N’DJAMENA: Thousands of people gathered at the main square in Chad’s capital N’Djamena on Friday to pay their respects to the late President Idriss Deby, who was killed while leading his troops against a rebel offensive on Monday.
French President Emmanuel Macron, Guinean President Alpha Conde and several other African leaders were expected to attend the funeral, despite rebel warnings they should not attend for security reasons.
Deby ruled Chad for more than 30 years and was one of Africa’s wiliest political survivors, holding on to power despite rebellions that reached as far as his palace gates.
Although criticized by human rights groups for his repressive rule, he established himself as a key military ally of Western powers in the international fight against Islamist militants.
“He liberated our country from dictatorship and gave us the opportunity to participate fully in democracy,” said Emmanuel Gaba, a young resident of the capital.
His death was announced by the army on Tuesday, a day after election officials said he had won a sixth term in office. Most of the opposition boycotted the vote.
“He protected us for so long that today we have come to wish him eternal rest. A deserved rest,” said Hassan Adoum, who attended the ceremony.
On Thursday a car with mounted speakers drove around N’Djamena telling residents not to panic if they hear cannon fire as Deby would receive a 21-gun salute.


German COVID cases not rising as rapidly, still too high

German COVID cases not rising as rapidly, still too high
Updated 23 April 2021

German COVID cases not rising as rapidly, still too high

German COVID cases not rising as rapidly, still too high
  • The number of new infections was rising in particular among those aged between 30 and 59
BERLIN: The number of new coronavirus cases does not appear to be rising as rapidly, the vice president of the Robert Koch Institute (RKI) for infectious diseases said on Friday, but warned that case numbers remained too high.
Lars Schaade told a weekly news conference that the number of new infections was rising in particular among those aged between 30 and 59 and said the virus was “not harmless” even for younger and healthier people.